Iimveliso

I-Fluorouracil antineoplastic iziyobisi zimveliso ze-fluorouracil.I-thymidine phosphorylase ekhoyo kwi-tumor tissue isebenza kuyo ukuyiguqula ibe yi-fluorochemicalbook uracil kwi-tumor, ngaloo ndlela yenza i-anti-tumor effect.Ukuchasana kwayo ne-tumor yomelele, kwaye ubuthi bayo buphantsi.Ekliniki isetyenziselwa umhlaza wesisu, umhlaza wesisu, umhlaza webele, izinga loxolelo linokufikelela ngaphezu kwama-30%.

Ukusebenza kwe-systemic chemotherapy yokusasazwa kwe-peritoneal yomhlaza wesisu kuhlala kungacaci.Ukusebenza kwe-paclitaxel yeveki ngokudibanisa ne-doxifluridine (5'-DFUR) kwizigulane zomhlaza wesisu ezine-ascites ezinobungozi zavavanywa.Izigulane ezinomhlaza wesisu oqinisekisiweyo we-histologically kunye ne-ascites zifanelekile.Unyango lwalubandakanya i-paclitaxel nge-intravenously (iv) elawulwa kwi-80 mg / m (2) kwiintsuku ze-1, i-8 kunye ne-15 kwiiveki ze-4, kwaye i-doxifluridine ilawulwa ngomlomo kwi-533 mg / m (2) kwiintsuku ze-1-5 ngeveki.Izinga lokuphendula kwizigulane ezine-ascites linqunywe ngokusekelwe kwi-Classification yaseJapan ye-Gastric Carcinoma.Kwakhona, ukuxinwa kwe-paclitaxel kwi-ascites kwalinganiswa.Izigulane ezingamashumi amabini anesine zaphandwa.Izinga lokuphendula (RR) laliyi-41.7%, kubandakanywa ukuxolelwa okupheleleyo (CR) kunye nokuxolelwa inxalenye (PR) kwi-4 kunye ne-6 izigulane, ngokulandelanayo.Uxinzelelo lwe-paclitaxel kwi-ascites lugcinwe phakathi kwe-0.01 μM kunye ne-0.05 μM ukuya kwiiyure ze-72.Ubomi obuqhelekileyo be-median (OS) yayiziintsuku ezingama-215, kwaye izinga lokusinda konyaka-1 lalingama-29.2%.Akukho tyhefu enzima yaqatshelwa.I-paclitaxel yeveki nganye idibene ne-doxifluridine iyasebenza kwizigulana zomhlaza wesisu esine-ascites enobungozi kunye neprofayili yetyhefu eyamkelekileyo.